Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is a morbid malignancy with
discouraging survival rates. Enthusiasm for pre-operative therapy (chemotherapy, radiation …

Objective: To establish an evidence-based cutoff and predictors for early recurrence in
patients with resected locally advanced pancreatic cancer (LAPC). Background: It is unclear …

Objective: This nationwide multicenter study aimed to define clinically relevant thresholds of
relative serum CA19-9 response after 2 months of induction chemotherapy in patients with …

Background: Previously considered inoperable patients (borderline resectable, locally
advanced, synchronous oligometastatic or metachronous pancreatic adenocarcinoma …

Simple Summary Pancreatic cancer is one of the deadliest cancers. It can only be cured by
surgery, and most people with pancreatic cancer are diagnosed when the cancer is too far …

Background The prognostic utility of Carbohydrate Antigen 19-9 (CA 19-9) and
Carcinoembryonic Antigen (CEA) in ampullary adenocarcinoma is unclear. We sought to …

Background Changes in tumor size and serum carbohydrate antigen 19-9 are commonly
reported markers used to assess response to neoadjuvant therapy in pancreatic ductal …

Importance Preoperative chemo (radio) therapy is increasingly used in patients with
localized pancreatic adenocarcinoma, leading to pathological complete response (pCR) in a …

Background In this era of increasing neoadjuvant chemotherapy, methods for evaluating
responses to neoadjuvant chemotherapy are still diverse among institutions. Additionally …